Episode Summary
Executive Summary: The episode traces the history of immunotherapy through William B. Coley’s late-19th-century experiments treating cancer with bacterial infections and bacterial toxins. It explains how Coley’s mixed toxins produced mixed but sometimes dramatic results, why his approach was controversial and eventually overshadowed by radiation and regulation, and how his work foreshadowed modern cancer immunology and BCG-based treatments.
Main Topics: Immunotherapy as a historical concept (Priority: 5/5): The hosts define immunotherapy broadly as immune-system modification and note the long history of related ideas, from variolation and vaccines to modern cancer treatment. William B. Coley and the origins of cancer immunotherapy (Priority: 5/5): The episode centers on Coley’s response to a young patient’s death and his investigation of cases where erysipelas infections appeared to shrink tumors. Coley’s experiments with erysipelas and bacterial toxins (Priority: 5/5): Coley first tried live bacterial infection, then shifted to killed cultures and filtered toxins, often using Streptococcus pyogenes and Bacillus prodigiosus, with some tumors shrinking or disappearing. Scientific controversy and clinical limitations (Priority: 4/5): His work was criticized for inconsistent results, difficult standardization, infection risk, and disagreements over whether successes were real cures or misdiagnoses. Coley’s legacy in modern cancer therapy (Priority: 5/5): The episode connects Coley’s ideas to later findings on BCG, TNF, and bladder cancer immunotherapy, showing that his work anticipated later immune-based cancer treatments. Regulation, competition, and decline of Coley’s toxins (Priority: 4/5): Radiation therapy, regulatory changes, and the challenge of producing standardized toxins contributed to the decline of Coley’s method despite later partial rehabilitation. Listener mail and lighter closing segment (Priority: 2/5): The episode ends with a listener email about a teen-made short film imagining Anne Bonny in the modern world, followed by hosts’ reactions.
Key Arguments: Coley’s work was one of the earliest deliberate attempts to use the immune system against cancer, even though he did not fully understand the mechanism. Some tumors, especially sarcomas, sometimes regressed dramatically after infection or toxin treatment, suggesting a real biological effect rather than pure coincidence. The treatment was dangerous and inconsistent, so Coley limited early use to inoperable cases where standard surgery had little chance of success. His mixed toxins were likely more important than live infection alone, and the fever/cytokine response may have contributed to antitumor effects. Modern immunotherapy validates parts of Coley’s intuition, even though his theory that all cancers had a microbial cause was wrong. Radiation therapy and regulatory hurdles helped push Coley’s approach to the margins before later immunology research partially revived interest in it.
Data Points: Age of first patient highlighted: 17 years old - Bessie Daschell, whose death prompted Coley to investigate cancer treatment alternatives Time from first exam to death: about 10 weeks - Bessie Daschell died shortly after Coley first examined her Medical school advance placement: entered as a second-year student - Coley skipped a year at Harvard Medical School due to prior experience with his physician uncle Initial patient records reviewed: about 90 cancer patients - Coley studied New York Hospital cases over the previous 15 years Early patient series: first 10 patients - Coley’s initial inoculation attempts with erysipelas in cancer patients Reported success rate: a little over 10% - Coley’s later claim about complete absorption/cure in some cases after toxin treatment Long-term survival in one report: 35 of 52 cases - Coley’s 1909 paper describing successful treatment of inoperable sarcoma Long-term follow-up range: 3.25 to 16 years - Duration of wellness among the 35 successful cases Coley reported Total patients treated: roughly 1,000 - Approximate number of cancer patients treated by Coley over about 40 years Number of papers published: about 150 - Coley’s published output on his toxin treatment work BCG bladder cancer approval year: 1990 - FDA approval of BCG for superficial bladder cancer Investigational drug classification year: 1963 - FDA classified Coley’s toxins as an investigational drug Cancer Research Institute trial year: 2007 - Phase one trial of Coley’s toxins funded by CRI
Pivotal Quotes: "In a certain number of cases, in my own experience, a little over 10%, the degenerative process has gone on until the complete absorption of the tumors has taken place and the patients have remained cured." — William B. Coley: Coley describing the outcomes of his mixed-toxin treatment in published work "The best method for the utilization of these toxins is not as yet positively determined. It is still under experiment and the results thus far demonstrate the necessity of great care in the culture of the bacteria and the preparation of their toxic products." — Journal of the American Medical Association: A contemporaneous editorial-like assessment of the treatment’s experimental status "The toxins were effective at inducing fever and robust surges in cytokines." — Cancer Research Institute blog post (quoted by hosts): Modern retrospective summary of why Coley’s toxins may have had biological effects
Implications: Coley’s story shows how early empirical observations can anticipate future breakthroughs, even when the original theory is wrong. Modern immunotherapy owes part of its lineage to his risky, inconsistent but visionary work.